Europe’s Pharmaceutical Industry at a Crossroads: The Squeeze Between American Ambition and Chinese Ascendancy
In the hushed laboratories of Basel, the gleaming research campuses outside Frankfurt, and the historic halls of Cambridge, Europe once dreamed of itself as the cradle of modern medicine. From the dye-works of 19th-century Germany that birthed aspirin and the sulfonamides, to the Swiss precision that gave the world Roche and Novartis, to the postwar miracle of insulin scaling and penicillin mass production, the continent’s pharmaceutical prowess was inseparable from its scientific enlightenment. Yet today, that inheritance feels less like a foundation than a fragile relic. Europe’s pharmaceutical industry stands at a perilous crossroads, caught between the unyielding commercial dynamism of the United States and the relentless, state-orchestrated surge of China. The question is no longer merely economic competitiveness; it is one of strategic autonomy, ethical responsibility, and the very soul of European humanism in an age of raw power…


